AI assistant
CANN GROUP LIMITED — Board/Management Information 2022
Aug 31, 2022
64603_rns_2022-08-31_ad7a5014-d54e-416e-b4b3-b770ec87d617.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [109 x 42] intentionally omitted <==
ASX ANNOUNCEMENT
1 September 2022
Resi nation of director g
1 September 2022 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) announce that John Sharman has resigned as a director of the company effective today due to his other business commitments. Mr Sharman was appointed to the Board of the Company on 27 April 2021.
Cann’s Chairman, Mr Allan McCallum, AO said “John has been a valuable member of the Board and we want to thank him sincerely for his contributions to the Company.”
As part of its ongoing review process, the Board is underway with the identification and appointment of a new director.
Authorised for release by the Board of Directors of Cann Group Limited.
For all media enquiries please contact:
Rhys Cohen Senior Corporate Communications Manager +61 449 679 095 [email protected]
For all other information please contact:
Peter Crock Deborah Ambrosini CEO CFO Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. Learn more at: www.canngrouplimited.com | www.satipharm.com
Cann Group Limited (ACN 603 949 739) 4 Research Avenue, Bundoora, VIC 3083 Australia Ph: +61 3 9095 7088